Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Conference Coverage

Molecular Classification With Modified ProMisE Algorithm Predicts Survival Outcomes Among Patients With Endometrial Cancer

Featuring Aine Clements, MD

 

Aine Clements, MD, Ohio Health, Columbus, Ohio, discussed ancillary results from the phase 3 GOG-0258 trial, as presented at the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting. 

Results from this ancillary analysis demonstrated that molecular classification based on a modified ProMisE algorithm is prognostic in endometrial cancer and patients with p53-abnormal tumors experience worse overall survival results. 


Source: 

Clements AE, Enserro D, Strickland KC, et al. Overall survival in patients in GOG-0258 by molecular classification with a modified ProMisE algorithm: Ancillary analysis of GOG-0258. Presented at the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting; March 16-18, 2024. San Diego, California

© 2024 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates. 

Advertisement

Advertisement

Advertisement

Advertisement